Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023
“Global vaccines market projected to grow at a CAGR of 6.7%”
The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development.
“Monovalent vaccines segment expected to hold the largest share of the market in 2018.”
Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.
“Pneumococcal disease segment is expected to hold largest share of the market in 2018”
Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share of the vaccines market in 2018. The large share of this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal diseases.
“Asia to witness high growth during the forecast period”
In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.
The primary interviews conducted for this report can be categorized as follows:
By Company Type: Tier 1 - 36%; Tier 2 - 41%; Tier 3 - 23%.
By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.
List of companies profiled in the report
GlaxoSmithKline plc (US)
Pfizer, Inc. (US)
Merck & Co., Inc. (US)
Sanofi Pasteur SA (France)
CSL Limited (Australia)
Emergent BioSolutions, Inc. (US)
Johnson & Johnson (US)
MedImmune, LLC (US)
Astellas Pharma Inc. (Japan)
Serum Institute of India (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo Company, Limited (Japan)
Biological E (India)
Panacea Biotec (India)
The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.